SummaryHypertension and dyslipidemias represent important risk factors for the occurrence of cardiovascular diseases which have a high mortality rate. Although we know how to treat both, the success rate remains low. More than half of patients need at least two antihypertensive agents to achieve target blood pressure. Also, dyslipidemia frequently coexists and thus the burden of life-long pill taking is high and the adherence is low. We suggest treating both conditions simultaneously in a fixed combination. This would increase patients' adherence and compliance to therapy and therefore provide a more successful management of both conditions.
References
1.
Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-Pill vs Free-Equivalent Combination Therapies for Hypertension: A Meta-Analysis of Health Care Costs and Adherence. The Journal of Clinical Hypertension. 2011;13(12):898–909.
2.
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis. The American Journal of Medicine. 2007;120(8):713–9.
3.
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet. 2002;360(9349):1903–13.
4.
Benner JS. Long-term Persistence in Use of Statin Therapy in Elderly Patients. JAMA. 2002;288(4):455.
5.
Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings C, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology. 2016;23(6):636–48.
6.
Chapman R, Benner J, Petrilla A, Tierce J, Battleman D, Schwartz J. PCV5 PREDICTORS OF ADHERENCE WITH CONCOMITANT ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY. Value in Health. 2004;7(3):319.
7.
Gupta AK, Arshad S, Poulter NR. Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents. Hypertension. 2010;55(2):399–407.
8.
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. The Lancet. 2007;370(9602):1829–39.
9.
Reiner Z, Catapano AL, De Backer G, Graham I, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal. 2011;32(14):1769–818.
10.
Jones PH, Nair R, Thakker KM. Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin‐Treated Subjects From 3 Data Sources: A Retrospective Analysis. Journal of the American Heart Association. 2012;1(6).
11.
BURNIER M. Medication Adherence and Persistence as the Cornerstone of Effective Antihypertensive Therapy. American Journal of Hypertension. 2006;19(11):1190–6.
12.
Giannattasio C, Cairo M, Cesana F, Alloni M, Sormani P, Colombo G, et al. Blood Pressure Control in Italian Essential Hypertensives Treated by General Practitioners. American Journal of Hypertension. 2012;25(11):1182–7.
13.
Fretheim A, Odgaard-Jensen J, Brørs O, Madsen S, Njølstad I, Norheim OF, et al. Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Medicine. 2012;10(1).
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
